Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy

被引：0
|
作者：
Hamfjord, J. [1 ]
Guren, T. [1 ]
Dajani, O. [1 ]
Glimelius, B. [2 ]
Sorbye, H. [3 ]
Pfeiffer, P. [4 ]
Christoffersen, T. [5 ]
Lingjaerde, O. [5 ]
Tveit, K. [1 ]
Kure, E. [1 ]
Pallisgaard, N. [6 ,7 ]
Spindler, K.
机构：
[1] Oslo Univ Hosp, Oslo, Norway
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Bergen, Haukeland Univ Hosp, Bergen, Norway
[4] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[5] Univ Oslo, Oslo, Norway
[6] Zealand Hosp, Roskilde, Denmark
[7] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 026
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery
    Shitara, Kohei
    Matsuo, Keitaro
    Kondo, Chihiro
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Kato, Mina
    Kanemitsu, Yukihide
    Komori, Koji
    Ishiguro, Seiji
    Sano, Tsuyoshi
    Shimizu, Yasuhiro
    Muro, Kei
    ONCOLOGY, 2011, 81 (3-4) : 167 - 174
  • [22] Preliminary results from a study of sevacizumab in Chinese patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
    Xu, Nong
    Cao, Junning
    Zhang, Yanqiao
    Ding, Yanhua
    Mao, Chenyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan- and/or oxaliplatin-based chemotherapy
    Catalano, V.
    D'Emidio, S.
    Loupakis, F.
    Graziano, F.
    Torresi, U.
    Mari, D.
    Bisonni, R.
    Giordani, P.
    Giustini, L.
    Falcone, A.
    Silva, R. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
    Papadaki, C.
    Saridaki, Z.
    Tzardi, M.
    Sfakianaki, M.
    Sfakiotaki, G.
    Trypaki, M.
    Messaritakis, I.
    Mavroudis, D.
    Georgoulias, V.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [25] TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
    Matsusaka, Satoshi
    Zhang, Wu
    Cao, Shu
    Hanna, Diana L.
    Sunakawa, Yu
    Sebio, Ana
    Ueno, Masashi
    Yang, Dongyun
    Ning, Yan
    Parekh, Anish
    Okazaki, Satoshi
    Berger, Martin D.
    Ichikawa, Wataru
    Mizunuma, Nobuyuki
    Lenz, Heinz-Josef
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (06) : 1405 - 1411
  • [26] Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study
    Marschner, Norbert
    Arnold, Dirk
    Engel, Erik
    Hutzschenreuter, Ulrich
    Rauh, Jacqueline
    Freier, Werner
    Hartmann, Holger
    Frank, Melanie
    Jaenicke, Martina
    CLINICAL EPIDEMIOLOGY, 2015, 7 : 295 - 303
  • [27] Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer
    Liu, Zhuo
    Kong, Jiangyin
    Kong, Yuanyuan
    Cai, Feng
    Xu, Xiaocheng
    Liu, Jun
    Wang, Shihua
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (11): : 1459 - 1468
  • [28] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [29] Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer
    Shyr, Bor-Uei
    Shyr, Bor-Shiuan
    Chen, Shih-Chin
    Chang, Shih-Ching
    Shyr, Yi-Ming
    Wang, Shin-E
    CANCERS, 2021, 13 (10)
  • [30] Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy
    Perez Martelo, M.
    Alvarez Fernandez, J.
    Abdulkader Nallib, I.
    Brozos Vazquez, E.
    Vazquez Rivera, F.
    Vidal Insua, Y.
    Candamio Folgar, S.
    Lopez Lopez, R.
    Ruiz Banobre, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S118 - S119
12345